Ndumele Chiadi E, Matsushita Kunihiro, Sang Yingying, Lazo Mariana, Agarwal Sunil K, Nambi Vijay, Deswal Anita, Blumenthal Roger S, Ballantyne Christie M, Coresh Josef, Selvin Elizabeth
From Johns Hopkins Ciccarone Center for the Prevention of Heart Disease(C.E.N., R.S.B.) and Department of General Internal Medicine(M.L., J.C., E.S.), Johns Hopkins University School of Medicine, Baltimore, MD; Department of Epidemiology and Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD(C.E.N., K.M., Y.S., M.L., J.C., E.S.); Division of Cardiology, Mount Sinai School of Medicine, New York, NY(S.K.A.); Division of Atherosclerosis and Vascular Medicine(V.N., C.M.B.) and Section of Cardiology(A.D.), Baylor College of Medicine, Houston, TX; Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart and Vascular Center, Houston, TX(V.N., C.M.B.); and Section of Cardiology, Michael E. DeBakey Veterans Affairs Medical Center, Houston TX(A.D., V.N.).
Circulation. 2016 Feb 16;133(7):631-8. doi: 10.1161/CIRCULATIONAHA.115.017298. Epub 2016 Jan 8.
Obesity is a risk factor for heart failure (HF) but is associated with lower N-terminal pro-brain natriuretic peptide (NT-proBNP) levels. It is unclear whether the prognostic value and implications of NT-proBNP levels for HF risk differ across body mass index (BMI) categories.
We followed up 12 230 ARIC participants free of prior HF at baseline (visit 2, 1990-1992) with BMI ≥18.5 kg/m(2). We quantified and compared the relative and absolute risk associations of NT-proBNP with incident HF across BMI categories. There were 1861 HF events during a median 20.6 years of follow-up. Despite increased HF risk in obesity, a weak inverse association was seen between baseline BMI and NT-proBNP levels (r=-0.10). Nevertheless, higher baseline NT-proBNP was associated with increased HF risk in all BMI categories. NT-proBNP improved HF risk prediction overall, even among those with severe obesity (BMI ≥35 kg/m(2); improvement in C statistic, 0.032; 95% confidence interval, 0.011-0.053). However, given the higher HF rates among those with obesity, at each NT-proBNP level, higher BMI was associated with greater absolute HF risk. Indeed, among those with NT-proBNP of 100 to <200 pg/mL, the average 10-year HF risk was <5% among normal-weight individuals but >10% among the severely obese.
Despite its inverse relationship with BMI, NT-proBNP provides significant prognostic information on the risk of developing HF even among individuals with obesity. Given the higher baseline HF risk among persons with obesity, even slight elevations in NT-proBNP may have implications for increased absolute HF risk in this population.
肥胖是心力衰竭(HF)的一个危险因素,但与较低的N末端脑钠肽前体(NT-proBNP)水平相关。目前尚不清楚NT-proBNP水平对HF风险的预后价值和影响在不同体重指数(BMI)类别中是否存在差异。
我们对12230名来自社区动脉粥样硬化风险研究(ARIC)的参与者进行了随访,这些参与者在基线时(1990 - 1992年第2次访视)无既往HF病史,BMI≥18.5kg/m²。我们对不同BMI类别中NT-proBNP与新发HF的相对和绝对风险关联进行了量化和比较。在中位20.6年的随访期间,共发生1861例HF事件。尽管肥胖会增加HF风险,但基线BMI与NT-proBNP水平之间存在微弱的负相关(r = -0.10)。然而,在所有BMI类别中,较高的基线NT-proBNP均与HF风险增加相关。NT-proBNP总体上改善了HF风险预测,即使在重度肥胖者(BMI≥35kg/m²)中也是如此(C统计量改善0.032;95%置信区间,0.011 - 0.053)。然而,鉴于肥胖者的HF发生率较高,在每个NT-proBNP水平上,较高的BMI与更高的绝对HF风险相关。事实上,在NT-proBNP为100至<200pg/mL的人群中,正常体重个体的平均10年HF风险<5%,而重度肥胖者中则>10%。
尽管NT-proBNP与BMI呈负相关,但即使在肥胖个体中,NT-proBNP也能提供有关发生HF风险的重要预后信息。鉴于肥胖者的基线HF风险较高,即使NT-proBNP略有升高也可能意味着该人群的绝对HF风险增加。